Innovation and the Burden of Disease: Retrospective Observational Study of New and Emerging Health Technologies Reported by the EuroScan Network from 2000 to 2009

Abstract

Innovations reported by early awareness and alert systems do not always reflect conditions accounting for the highest morbidity and mortality. The results do not support previous reports of a positive relationship between burden of disease and innovation, but accord with evidence of notable discrepancies among key groups. Factors other than disease burden drive innovation.

Análise de medicamentos novos registrados no Brasil na perspectiva do Sistema Único de Saúde e da carga de doença

“…The process of developing new technologies in healthcare, particularly drugs, is long, costly, subject to failure and driven by commercial perspectives 12,41 . The drugs used in primary care are indicated for the prevention and control of major diseases from an epidemiological point of view, however their cost is not high when compared to the specialized component 36 .…”

“…Specialized component drugs have a significant budget impact due to high unit value and treatment chronicity 5,36 . Health innovation reflects all the factors that influence the return on investment, and the burden of disease is just one of the factors 12,41 . The absence of new drugs for use in primary care can be explained by economic and market determinants that influence the pharmaceutical industry at the expense of national health priorities 12,39,41,44 .…”

“…Health innovation reflects all the factors that influence the return on investment, and the burden of disease is just one of the factors 12,41 . The absence of new drugs for use in primary care can be explained by economic and market determinants that influence the pharmaceutical industry at the expense of national health priorities 12,39,41,44 . Important measures to optimize the use of new health system-funded drugs include therapeutic clinical guidelines, restriction criteria for prescriptions, effectiveness, and security monitoring 1,3 .…”

“…Burden of disease is recommended by the World Health Organization (WHO) to define priority drugs for health systems, and various methodologies are used to measure it. The most described methodology employs the DALY (disability-adjusted life year) indicator, a simultaneous measure of mortality and disability of a particular disease or health condition 2,[9][10][11][12] . In Brazil, this indicator of disease burden was used to analyze the essential drugs selection system 13 , however research related to new drugs has not been published to date.…”

Bibliometric analysis of international researches on innovation metrics

“…Table 7 shows the distribution of researches in relation to the level of analysis for further discussion. Table 7 Levels of analysis of the selected papers Martino et al (2012) and Amore et al (2013) Energy Noailly (2012) and Bettencourt et al (2013) Among the selected studies, the firm stands out as main level of analysis. This fact stems from the fact that the firm is responsible for adding value to the resources it receives and by selling them as products to the market.…”